Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting
November 05, 2024 09:00 ET
|
Ichnos Glenmark Innovation
IGI Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma at ASH
Dr. Wenming Chen to Receive Asian Myeloma Network Distinguished Service Award at the 8th AMN Summit in Seoul
October 17, 2024 10:41 ET
|
International Myeloma Foundation
SEOUL, South Korea, Oct. 17, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) announced that it will be holding the Asian Myeloma Network (AMN) awards ceremony on Saturday,...
International Myeloma Foundation Launches Clinical Trial Matching Engine in Partnership with SparkCures
October 10, 2024 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to announce that it has partnered with SparkCures to bring an innovative solution to...
International Myeloma Foundation to Hold First Latin American Myeloma Network Summit in Brazil on September 28
September 26, 2024 08:45 ET
|
International Myeloma Foundation
RIO DE JANEIRO, Brazil, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce that the inaugural IMF Latin American Myeloma Network (LAMN) Summit will be...
International Myeloma Foundation Launches Myelo: The First AI-Powered Responsive Chatbot to Provide Compassionate Myeloma Support for Patients, Care Partners, and Healthcare Professionals
September 19, 2024 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the launching of Myelo—the first AI-powered responsive chatbot designed to act...
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
September 11, 2024 05:00 ET
|
Ichnos Glenmark Innovation
Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity
The International Myeloma Foundation (IMF) Brings Back ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2024
August 29, 2024 08:45 ET
|
International Myeloma Foundation
LOS ANGELES, Aug. 29, 2024 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma Foundation (IMF) is reviving and amplifying its highly successful...
Multiple Myeloma Research Foundation (MMRF) Announces New Publication on CoMMpass℠ Study in Nature Genetics Defining Distinct Subtypes of Multiple Myeloma and High-Risk Genetic Markers
August 19, 2024 05:05 ET
|
Multiple Myeloma Research Foundation
This MMRF-led collaborative initiative is the largest single sequencing study of multiple myeloma patients to dateCoMMpass findings provide an unprecedented, clearer definition of patients at highest...
International Myeloma Foundation Medical Student Scholars for Health Equity in Myeloma Present Posters at the 2024 NMA Annual Convention & Scientific Assembly
August 15, 2024 08:45 ET
|
International Myeloma Foundation
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF), in partnership with the National Medical Association (NMA), the W. Montague Cobb Institute, and the Student...
Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma
July 23, 2024 08:00 ET
|
Bionano Genomics
SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome...